clinical trial · NCT07291076
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb·phase2·recruiting·n = 129
Hepatocellular Carcinoma (HCC)PumitamigIpilimumabAtezolizumabBevacizumab
brief summary
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
started
Mar 16, 2026
primary completion
Oct 15, 2029
completion
Oct 14, 2031
last updated
May 14, 2026
official title
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol